Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteonecrosis of the jaw related to bevacizumab.

× No keyword cloud information.

49 in total

Review 1. A systematic review of bisphosphonate osteonecrosis (BON) in cancer.

Authors: Cesar Augusto Migliorati; Sook-Bin Woo; Ian Hewson; Andrei Barasch; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal: Support Care Cancer Date: 2010-04-22 Impact factor: 3.603

2. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

Authors: Nancy E Kemeny; William R Jarnagin; Marinela Capanu; Yuman Fong; Alexandra N Gewirtz; Ronald P Dematteo; Michael I D'Angelica
Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544

3. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors: Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal: J Bone Miner Metab Date: 2010-03-24 Impact factor: 2.626

4. Bevacizumab-associated osteonecrosis of the jaw.

Authors: S Greuter; F Schmid; T Ruhstaller; B Thuerlimann
Journal: Ann Oncol Date: 2008-10-31 Impact factor: 32.976

5. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors: Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal: BMJ Case Rep Date: 2012-10-22

6. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Authors: K M Kim; W Park; S Y Oh; H-J Kim; W Nam; S-K Lim; Y Rhee; I H Cha
Journal: Osteoporos Int Date: 2014-02-20 Impact factor: 4.507

Review 7. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors: Maya B Lodish
Journal: J Clin Endocrinol Metab Date: 2013-02-28 Impact factor: 5.958

8. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors: Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal: Support Care Cancer Date: 2018-10-23 Impact factor: 3.603

9. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.

Authors: Daria Pakosch; Dimitrios Papadimas; Johanna Munding; Darafsch Kawa; Marcus Stephan Kriwalsky
Journal: Oral Maxillofac Surg Date: 2012-12-16

10. Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature.

Authors: Nicole M Agostino; Rebecca Gingrich; Joseph J Drabick
Journal: Adv Urol Date: 2010-07-20